{"transactions":[{"id":690423,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-08-11T20:40:52.000Z","date":"2026-08-07","kind":"grant","planned":false,"acquired":true,"shares":22350,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":22350,"derivative":{"exercise_price":4.14,"expiration_date":"2036-08-06","underlying":"Class A Common Stock","underlying_shares":22350},"source":{"system":"sec-edgar","filing":"0001547100-26-000005","document":"form4-08112026_080842.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000005/form4-08112026_080842.xml","form_type":"4"}},{"id":729201,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-23T21:01:07.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":6212,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2027 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":6212,"derivative":{"exercise_price":70.79,"expiration_date":"2036-06-17","underlying":"Common Stock","underlying_shares":6212},"source":{"system":"sec-edgar","filing":"0001193125-26-279734","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312526279734/ownership.xml","form_type":"4"}},{"id":741986,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-12T00:00:05.000Z","date":"2026-06-09","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest in full upon the earlier of (i) June 9, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":6.69,"expiration_date":"2036-06-08","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0001193125-26-268165","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000119312526268165/ownership.xml","form_type":"4"}},{"id":745835,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-06-08T22:27:29.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":1275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"100% of the shares subject to the option will vest on the earlier of June 4, 2027 or the day prior to the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person continuing as a service provider through the applicable vesting date."}],"balance_after":1275,"derivative":{"exercise_price":4.3,"expiration_date":"2036-06-03","underlying":"Class A Common Stock","underlying_shares":1275},"source":{"system":"sec-edgar","filing":"0001547100-26-000004","document":"form4-06082026_100623.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000004/form4-06082026_100623.xml","form_type":"4"}},{"id":822561,"issuer":{"id":6550,"kind":"organization","name":"OnKure Therapeutics, Inc.","symbol":"OKUR"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-04-01T21:25:43.000Z","date":"2026-03-31","kind":"grant","planned":false,"acquired":true,"shares":15300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/36th of the shares subject to the option shall vest on April 30, 2026 and on the last day of each month thereafter, subject to the Reporting Person continuing as a service provider through each such date."}],"balance_after":15300,"derivative":{"exercise_price":4.14,"expiration_date":"2036-03-30","underlying":"Class A Common Stock","underlying_shares":15300},"source":{"system":"sec-edgar","filing":"0001547100-26-000003","document":"form4-04012026_090435.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000154710026000003/form4-04012026_090435.xml","form_type":"4"}},{"id":1111858,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T21:29:57.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2026 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":50.86,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-25-086393","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017025086393/ownership.xml","form_type":"4"}},{"id":1113802,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-12T20:17:20.000Z","date":"2025-06-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":11.59,"expiration_date":"2035-06-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-25-085370","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017025085370/ownership.xml","form_type":"4"}},{"id":1386800,"issuer":{"id":5743,"kind":"organization","name":"Upstream Bio, Inc.","symbol":"UPB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-15T20:15:06.000Z","date":"2024-10-10","kind":"grant","planned":false,"acquired":true,"shares":17096,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) October 10, 2025 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":17096,"derivative":{"exercise_price":17,"expiration_date":"2034-10-09","underlying":"Common Stock","underlying_shares":17096},"source":{"system":"sec-edgar","filing":"0000950170-24-114681","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2022626/000095017024114681/ownership.xml","form_type":"4"}},{"id":1467022,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2024-06-28T21:09:06.000Z","date":"2024-06-26","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of June 26, 2025 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":10000,"derivative":{"exercise_price":7.89,"expiration_date":"2034-06-25","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001415889-24-018461","document":"form4-06282024_090603.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000141588924018461/form4-06282024_090603.xml","form_type":"4"}},{"id":1479195,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-14T20:15:06.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2025 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":38.85,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000950170-24-073672","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000095017024073672/ownership.xml","form_type":"4"}},{"id":1860801,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-09T22:20:31.000Z","date":"2023-06-09","kind":"grant","planned":false,"acquired":true,"shares":7136,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2024 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":7136,"derivative":{"exercise_price":45.69,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":7136},"source":{"system":"sec-edgar","filing":"0000899243-23-015267","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924323015267/doc4.xml","form_type":"4"}},{"id":1882191,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2023-05-22T21:11:11.000Z","date":"2023-05-18","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 18, 2024 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":10000,"derivative":{"exercise_price":3,"expiration_date":"2033-05-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-23-031535","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919123031535/doc4.xml","form_type":"4"}},{"id":2072803,"issuer":{"id":2273,"kind":"organization","name":"Disc Medicine, Inc.","symbol":"IRON"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-03T22:05:47.000Z","date":"2022-12-29","kind":"grant","acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option vest upon the first to occur of (i) the date of the Company's 2023 annual meeting of its stockholders, or (ii) the one-year anniversary of the grant date, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":7000,"derivative":{"exercise_price":13.5,"expiration_date":"2032-12-28","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0000899243-23-000301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816736/000089924323000301/doc4.xml","form_type":"4"}},{"id":2224959,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-22T00:00:45.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":10192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 16, 2022. The shares underlying the award shall vest in full on the earlier of June 16, 2023 or the first meeting of the board of directors of the Issuer held after the following annual meeting of stockholders."}],"balance_after":10192,"derivative":{"exercise_price":36.79,"expiration_date":"2032-06-15","underlying":"Common Stock","underlying_shares":10192},"source":{"system":"sec-edgar","filing":"0001209191-22-038558","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919122038558/doc4.xml","form_type":"4"}},{"id":2249122,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2022-06-01T21:14:32.000Z","date":"2022-05-19","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option will vest on the earlier of May 19, 2023 or the day immediately prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date."}],"balance_after":10000,"derivative":{"exercise_price":3.46,"expiration_date":"2032-05-18","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001209191-22-033220","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919122033220/doc4.xml","form_type":"4"}},{"id":2469533,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":37206,"price":68.9682,"value":2566030.8492,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.275 to $68.335, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":185686,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469532,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-16","kind":"sale","acquired":false,"shares":48499,"price":69.6589,"value":3378386.9911,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.28 to $69.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":222892,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469531,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":5695,"price":65.7359,"value":374365.9505,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.92 to $65.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":271391,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469530,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":67549,"price":66.5047,"value":4492325.9803,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.93 to $65.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":277086,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469529,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-15","kind":"sale","acquired":false,"shares":40292,"price":67.4643,"value":2718271.5756,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.94 to $66.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":344635,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469528,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":700,"price":64.2018,"value":44941.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.34 to $64.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":384927,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469527,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":36308,"price":65.3839,"value":2373958.6412,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.665 to $64.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":385627,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2469526,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-12-17T02:30:24.000Z","date":"2021-12-14","kind":"sale","acquired":false,"shares":119456,"price":66.0084,"value":7885099.4304,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.66 to $65.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":421935,"source":{"system":"sec-edgar","filing":"0000899243-21-048686","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321048686/doc4.xml","form_type":"4"}},{"id":2512349,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":3532,"price":83.9035,"value":296347.162,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.75 to $84.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (14)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":541391,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512348,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-15","kind":"sale","acquired":false,"shares":17752,"price":85.0677,"value":1510121.8104,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.57 to $85.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (13)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":544923,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512347,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":12760,"price":84.0204,"value":1072100.304,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.115, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (12)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":562675,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512346,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":9660,"price":84.3141,"value":814474.206,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.14 to $85.12, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (11)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":575435,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512345,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":17449,"price":85.9583,"value":1499886.3767,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.15 to $86.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":585095,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512344,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-11","kind":"sale","acquired":false,"shares":36210,"price":85.9247,"value":3111333.387,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.25 to $86.055, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":602544,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512343,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-11","kind":"sale","acquired":false,"shares":18007,"price":86.3813,"value":1555468.0691,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.06 to $87.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":638754,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512342,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-11","kind":"sale","acquired":false,"shares":5582,"price":87.7089,"value":489591.0798,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.07 to $88.065, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":656761,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512341,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":199,"price":86.5861,"value":17230.6339,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.57 to $86.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":662343,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512340,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":3956,"price":87.1143,"value":344624.1708,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.65 to $87.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":662542,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512339,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":5853,"price":88.1189,"value":515759.9217,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.66 to $88.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":666498,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512338,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":1498,"price":89.1588,"value":133559.8824,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.68 to $89.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":672351,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2512337,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-16T02:45:43.000Z","date":"2021-11-10","kind":"sale","acquired":false,"shares":1852,"price":90.18,"value":167013.36,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.75 to $90.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":673849,"source":{"system":"sec-edgar","filing":"0000899243-21-044697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321044697/doc4.xml","form_type":"4"}},{"id":2519168,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"exercise","acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F21","text":"This option award was granted on June 3, 2020 and the shares underlying the award vested in full on June 3, 2021."}],"balance_after":0,"derivative":{"exercise_price":33.57,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519167,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"exercise","acquired":false,"shares":6423,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020."}],"balance_after":0,"derivative":{"exercise_price":22.06,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":6423},"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519166,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":580,"price":91.3256,"value":52968.848,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $91.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (19)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":675701,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519165,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":27297,"price":91.845,"value":2507092.965,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.37 to $92.365, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (18)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":676281,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519164,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-09","kind":"sale","acquired":false,"shares":5131,"price":92.7304,"value":475799.6824,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.37 to $93.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (17)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":703578,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519163,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":3688,"price":92.476,"value":341051.488,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.03 to $92.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (16)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":708709,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519162,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":11130,"price":93.032,"value":1035446.16,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.67 to $93.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (15)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":712397,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519161,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":11668,"price":94.2003,"value":1099129.1004,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.71 to $94.71, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (14)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":723527,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519160,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-08","kind":"sale","acquired":false,"shares":54568,"price":94.9321,"value":5180254.8328,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.72 to $95.715, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (13)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":735195,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519159,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":2747,"price":89.863,"value":246853.661,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.51 to $90.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (12)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":789763,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519158,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":8676,"price":91.0904,"value":790300.3104,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.42 to $91.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (11)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":792510,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519157,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":15327,"price":91.8147,"value":1407243.9069,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.42 to $92.42, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":801186,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519156,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":1825,"price":93.033,"value":169785.225,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.52 to $93.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":816513,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519155,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":4519,"price":94.0775,"value":425136.2225,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.75 to $94.51, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the reporting person is the holder of units that are treated as profits interest units. The units owned by the reporting person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The reporting person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":818338,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519154,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":484,"price":89.65,"value":43390.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.57 to $89.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6)."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519153,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":795,"price":90.29,"value":71780.55,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.11 to $90.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5)."}],"balance_after":484,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519152,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":5221,"price":91.59,"value":478191.39,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $92.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4)."}],"balance_after":1279,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519151,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":4940,"price":90.75,"value":448305.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.75 to $90.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3)."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519150,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":7060,"price":91.5,"value":645990.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.15 to $92.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2)."}],"balance_after":11440,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519149,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"sale","acquired":false,"shares":6423,"price":91.5,"value":587704.5,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $91.27 to $91.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the Staff of the Securities and Exchange Commission (the \"SEC\"), upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (1)."}],"balance_after":18500,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519148,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"exercise","acquired":true,"shares":12000,"price":33.57,"value":402840.0,"ownership":{"direct":true},"balance_after":24923,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2519147,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-11-10T02:47:09.000Z","date":"2021-11-05","kind":"exercise","acquired":true,"shares":6423,"price":22.06,"value":141691.38,"ownership":{"direct":true},"balance_after":12923,"source":{"system":"sec-edgar","filing":"0000899243-21-043795","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924321043795/doc4.xml","form_type":"4"}},{"id":2606511,"issuer":{"id":5064,"kind":"organization","name":"Climb Bio, Inc.","symbol":"CLYM"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-08-11T21:23:58.000Z","date":"2021-08-09","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"For so long as the Reporting Person continuously provides services to the Issuer, this option will vest with respect to the shares as follows: 1/36th of the shares will vest on each monthly anniversary of August 1, 2021."}],"balance_after":20000,"derivative":{"exercise_price":12.5,"expiration_date":"2031-08-08","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-21-050959","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919121050959/doc4.xml","form_type":"4"}},{"id":2673422,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-06-11T00:00:47.000Z","date":"2021-06-08","kind":"grant","acquired":true,"shares":7511,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 8, 2021. The shares underlying the award shall vest in full on June 8, 2022 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":7511,"derivative":{"exercise_price":78.53,"expiration_date":"2021-06-07","underlying":"Common Stock","underlying_shares":7511},"source":{"system":"sec-edgar","filing":"0001209191-21-039678","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919121039678/doc4.xml","form_type":"4"}},{"id":2690814,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-28T21:58:14.000Z","date":"2021-05-27","kind":"grant","acquired":true,"shares":16918,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as of 1/12 of the total shares monthly beginning on June 27, 2021 until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":16918,"derivative":{"exercise_price":13.83,"expiration_date":"2031-05-26","underlying":"Common Stock","underlying_shares":16918},"source":{"system":"sec-edgar","filing":"0001209191-21-036622","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919121036622/doc4.xml","form_type":"4"}},{"id":2935818,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-21T23:00:08.000Z","date":"2020-12-18","kind":"purchase","acquired":true,"shares":142857,"price":70,"value":9999990.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":822857,"source":{"system":"sec-edgar","filing":"0001209191-20-064697","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120064697/doc4.xml","form_type":"4"}},{"id":3121653,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-06-05T01:00:11.000Z","date":"2020-06-03","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on June 3, 2020. The shares underlying the award shall vest in full on June 3, 2021 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":12000,"derivative":{"exercise_price":33.57,"expiration_date":"2030-06-02","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-20-034584","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120034584/doc4.xml","form_type":"4"}},{"id":3133244,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2020-05-27T22:34:04.000Z","date":"2020-05-26","kind":"exercise","acquired":false,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option award was granted on May 23, 2019 and the shares underlying the award vested in full on May 23, 2020."}],"balance_after":6423,"derivative":{"exercise_price":22.06,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001209191-20-032410","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120032410/doc4.xml","form_type":"4"}},{"id":3133243,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-05-27T22:34:04.000Z","date":"2020-05-26","kind":"exercise","acquired":true,"shares":6500,"price":22.06,"value":143390.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001209191-20-032410","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120032410/doc4.xml","form_type":"4"}},{"id":3210444,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-03-13T21:20:32.000Z","date":"2020-03-03","kind":"exercise","acquired":false,"shares":2066630,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By AI Passage LLC"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2066630},"source":{"system":"sec-edgar","filing":"0001209191-20-018974","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120018974/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3210443,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T21:20:32.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":2800,"price":18,"value":50400.0,"ownership":{"direct":true},"balance_after":2800,"source":{"system":"sec-edgar","filing":"0001209191-20-018974","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120018974/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3210442,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T21:20:32.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":550000,"price":18,"value":9900000.0,"ownership":{"direct":false,"nature":"By AI Passage LLC"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error."}],"balance_after":2616630,"source":{"system":"sec-edgar","filing":"0001209191-20-018974","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120018974/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3210441,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-13T21:20:32.000Z","date":"2020-03-03","kind":"exercise","acquired":true,"shares":2066630,"ownership":{"direct":false,"nature":"By AI Passage LLC"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the issuer's Series B Preferred Stock automatically converted into one (1) share of the issuer's Common Stock immediately upon the closing of the issuer's initial public offering on March 3, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported shares are held indirectly by a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the issuer's Common Stock. The Reporting Person disclaims beneficial ownership of all shares held by AI Passage LLC and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein. The reported shares were erroneously excluded from the Reporting Person's original Form 4 due to an administrative error."}],"balance_after":2066630,"source":{"system":"sec-edgar","filing":"0001209191-20-018974","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120018974/doc4a.xml","form_type":"4/A","original_submission_date":"2020-03-03"}},{"id":3230862,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-03T23:48:36.000Z","date":"2020-03-03","kind":"purchase","acquired":true,"shares":2800,"price":18,"value":50400.0,"ownership":{"direct":true},"balance_after":2800,"source":{"system":"sec-edgar","filing":"0001209191-20-015640","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120015640/doc4.xml","form_type":"4"}},{"id":3237342,"issuer":{"id":7829,"kind":"organization","name":"Passage BIO, Inc."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-03-02T22:58:27.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":33836,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vest as to 2.778% of the total shares monthly, commencing March 27, 2020, with 100% of the total shares vested on February 27, 2023, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":33836,"derivative":{"exercise_price":18,"expiration_date":"2030-02-27","underlying":"Common Stock","underlying_shares":33836},"source":{"system":"sec-edgar","filing":"0001209191-20-014700","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919120014700/doc4.xml","form_type":"4"}},{"id":3370979,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-11-14T21:23:34.000Z","date":"2019-11-12","kind":"purchase","acquired":true,"shares":680000,"price":22,"value":14960000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported shares are held directly by AI Biotechnology LLC (\"AIB\"), a limited liability company of which the Reporting Person is the holder of units that are treated as profits interest units. The units owned by the Reporting Person do not convey a right to vote or dispose of the shares of the Issuer's Common Stock held by AIB. The Reporting Person disclaims beneficial ownership of all shares held by AIB and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein."}],"balance_after":680000,"source":{"system":"sec-edgar","filing":"0000899243-19-027280","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924319027280/doc4.xml","form_type":"4"}},{"id":3485705,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-18T20:27:45.000Z","date":"2019-06-14","kind":"grant","acquired":true,"shares":7881,"price":1.6654,"value":13125.0174,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":7881,"derivative":{"exercise_price":2.43,"expiration_date":"2029-06-14","underlying":"Common Stock","underlying_shares":7881},"source":{"system":"sec-edgar","filing":"0001209191-19-037693","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919119037693/doc4.xml","form_type":"4"}},{"id":3509888,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-05-28T21:11:43.000Z","date":"2019-05-23","kind":"grant","acquired":true,"shares":12923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option award was granted on May 23, 2019. The shares underlying the award shall vest in full on May 23, 2020 or, if earlier, the date of the first meeting of the board of directors of the Issuer held after the Issuer's next annual meeting of stockholders."}],"balance_after":12923,"derivative":{"exercise_price":22.06,"expiration_date":"2029-05-22","underlying":"Common Stock","underlying_shares":12923},"source":{"system":"sec-edgar","filing":"0000899243-19-014879","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924319014879/doc4.xml","form_type":"4"}},{"id":3563796,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-03T20:32:25.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":4829,"price":2.7185,"value":13127.6365,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":4829,"derivative":{"exercise_price":4.4,"expiration_date":"2029-04-01","underlying":"Common Stock","underlying_shares":4829},"source":{"system":"sec-edgar","filing":"0001209191-19-023141","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919119023141/doc4.xml","form_type":"4"}},{"id":3568889,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-02T16:24:06.000Z","date":"2019-03-29","kind":"grant","acquired":true,"shares":4123,"price":2.425,"value":9998.275,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take equity awards in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":4123,"derivative":{"exercise_price":4.05,"expiration_date":"2029-03-28","underlying":"Common Stock","underlying_shares":4123},"source":{"system":"sec-edgar","filing":"0001104659-19-019381","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465919019381/a4.xml","form_type":"4"}},{"id":3590495,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2019-03-18T21:52:45.000Z","date":"2019-03-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of RSUs granted to the Reporting Person on August 14, 2018."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001127602-19-011935","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219011935/form4.xml","form_type":"4"}},{"id":3590494,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true}}],"security":"Common Stock","published_at":"2019-03-18T21:52:45.000Z","date":"2019-03-15","kind":"exercise","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Vesting of RSUs granted to the Reporting Person on August 14, 2018."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001127602-19-011935","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760219011935/form4.xml","form_type":"4"}},{"id":3703171,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-04T21:57:23.000Z","date":"2019-01-02","kind":"grant","acquired":true,"shares":4860,"price":2.7,"value":13122.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":4860,"derivative":{"exercise_price":4.47,"expiration_date":"2029-01-02","underlying":"Common Stock","underlying_shares":4860},"source":{"system":"sec-edgar","filing":"0001209191-19-002049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919119002049/doc4.xml","form_type":"4"}},{"id":3797911,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":568252,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"NLV-III Manager\" and collectively, the \" NLV-III Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":174846},"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797910,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"exercise","acquired":false,"shares":3601657,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"NLV-III Manager\" and collectively, the \" NLV-III Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1108202},"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797909,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":375000,"price":16,"value":6000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities II, L.P. (\"BPO-II\"). The general partner of BPO-II is New Leaf BPO Associates II, L.P. (\"NLBA-II\"). The general partner of NLBA-II is New Leaf BPO Management II, L.L.C. (\"BPO Management-II\"). Each of NLBA-II and BPO Management-II disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-II or BPO Management-II are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt, Vijay K. Lathi and Isaac J. Manke are the managers of BPO Management-II (each, a \"BPO-II Manager\" and collectively, the \"BPO-II Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"(Continued from Footnote 4) The Reporting Person and each of the BPO-II Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":375000,"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797908,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"purchase","acquired":true,"shares":625000,"price":16,"value":10000000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"NLV-III Manager\" and collectively, the \" NLV-III Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1908048,"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797907,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":174846,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"NLV-III Manager\" and collectively, the \" NLV-III Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1283048,"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797906,"issuer":{"id":5355,"kind":"organization","name":"ARVINAS, INC."},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-10-03T21:22:28.000Z","date":"2018-10-01","kind":"exercise","acquired":true,"shares":1108202,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"All Series B Preferred Stock and Series C Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 3.25-for-one basis upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"NLV-III Manager\" and collectively, the \" NLV-III Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"(Continued from Footnote 2) The Reporting Person and each of the NLV-III Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1108202,"source":{"system":"sec-edgar","filing":"0000899243-18-026073","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000089924318026073/doc4.xml","form_type":"4"}},{"id":3797901,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-03T21:19:22.000Z","date":"2018-10-01","kind":"grant","acquired":true,"shares":2111,"price":6.22,"value":13130.42,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":2111,"derivative":{"exercise_price":10.37,"expiration_date":"2028-10-01","underlying":"Common Stock","underlying_shares":2111},"source":{"system":"sec-edgar","filing":"0001209191-18-053976","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919118053976/doc4.xml","form_type":"4"}},{"id":3807075,"issuer":{"id":3793,"kind":"organization","name":"Cogent Biosciences, Inc.","symbol":"COGT"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-09-26T22:47:21.000Z","date":"2018-07-26","kind":"grant","acquired":true,"shares":1504,"price":8.72,"value":13114.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The option award was issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation plan. The number of options granted was determined by dividing the cash compensation otherwise payable with respect to the quarter by the Black-Scholes value of a single option calculated as of the date of the grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is fully vested at time of grant."}],"balance_after":1504,"derivative":{"exercise_price":14.57,"expiration_date":"2028-07-26","underlying":"Common Stock","underlying_shares":1504},"source":{"system":"sec-edgar","filing":"0001209191-18-052365","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1547100/000120919118052365/doc4.xml","form_type":"4"}},{"id":3843289,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true}}],"security":"Restricted Stock Units","published_at":"2018-08-15T12:05:33.000Z","date":"2018-08-14","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of Edge common stock upon the vesting of such unit."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Expiration date is not applicable as the vested restricted stock units shall be settled on the first business day following the date that such restricted stock units vest."}],"balance_after":10000,"derivative":{"underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001127602-18-025376","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760218025376/form4.xml","form_type":"4"}},{"id":3883161,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":6712986,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":243345},"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883160,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":15233315,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":552208},"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883159,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-2 Convertible Preferred Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":33022786,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1197076},"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883158,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Convertible Preferred Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":false,"shares":28895188,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1047450},"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883157,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":368345,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883156,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":125000,"price":16,"value":2000000.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"On June 25, 2018, each of NLV-III and NLV Biopharma purchased 125,000 and 125,000 shares of common stock of the Issuer at a price of $16.00 per share, respectively, pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2921734,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883155,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":243345,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by New Leaf Ventures Biopharma Opportunities I, L.P. (\"NLV Biopharma\"). The general partner of NLV Biopharma is New Leaf BPO Associates I, L.P. (\"NLBA-I\"). The general partner of NLBA-I is Management-III. Each of NLBA-I and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLBA-I and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLBA-I or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person and each of the Managers may be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":243345,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883154,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":552208,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2796734,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883153,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1197076,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":2244526,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3883152,"issuer":{"id":120922,"kind":"organization","name":"Aptinyx Inc.","symbol":"APTX"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-06-26T16:53:54.000Z","date":"2018-06-25","kind":"exercise","acquired":true,"shares":1047450,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of  Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 27.58621-for-one basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration.  The shares of Series A-1 Convertible Preferred Stock, Series A-2 Convertible Preferred Stock and Series B Convertible Preferred Stock had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). The general partner of NLV-III is New Leaf Venture Associates III, L.P. (\"NLVA-III\"). The general partner of NLVA-III is New Leaf Venture Management III, L.L.C. (\"Management-III\"). Each of NLVA-III and Management-III may be deemed to have sole voting and investment power with respect to these securities. Each of NLVA-III and Management-III disclaim beneficial ownership of these securities and this report shall not be deemed an admission that NLVA-III or Management-III are beneficial owners of such securities for purposes of Section 16 or any other purpose, except to the extent of their respective pecuniary interests therein. The Reporting Person, a member of the Issuer's board of directors, Ronald M. Hunt and Vijay K. Lathi are the managers of Management-III (each, a \"Manager\" and collectively, the \"Managers\") and may each be deemed to have shared voting and investment power with respect to these securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person and each of the Managers disclaims beneficial ownership of these securities and this report shall not be deemed an admission that any of them is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their respective pecuniary interests therein."}],"balance_after":1047450,"source":{"system":"sec-edgar","filing":"0001104659-18-042308","document":"a4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1674365/000110465918042308/a4.xml","form_type":"4"}},{"id":3887139,"issuer":{"id":7939,"kind":"organization","name":"PDS Biotechnology Corp","symbol":"PDSB"},"owners":[{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":1,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":true}}],"security":"Stock Option (Right To Purchase)","published_at":"2018-06-20T20:54:53.000Z","date":"2018-06-19","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These options shall become exercisable upon the achievement of certain performance or time based criteria."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These options expire on the third anniversary of the vesting date."}],"balance_after":20000,"derivative":{"exercise_price":1.1,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001127602-18-021621","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1472091/000112760218021621/form4.xml","form_type":"4"}},{"id":3912134,"issuer":{"id":72802,"kind":"organization","name":"Iterum Therapeutics plc","symbol":"ITRM"},"owners":[{"id":93225,"kind":"person","name":"Lathi Vijay K","position":1,"cik":"0001340806","reported_name":"Lathi Vijay K","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":24504,"kind":"person","name":"Ratcliffe Liam","position":2,"cik":"0001547100","reported_name":"Ratcliffe Liam","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B-2 Preferred Shares","published_at":"2018-05-31T16:54:17.000Z","date":"2018-05-30","kind":"exercise","acquired":false,"shares":148603,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By New Leaf Ventures III, L.P."},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Not applicable."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held directly by New Leaf Ventures III, L.P. (\"NLV-III\"). New Leaf Venture Associates III, L.P. (\"NLVA-III LP\") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. (\"NLVM-III LLC\") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. Vijay Lathi, Liam Ratcliffe and Ronald Hunt, a member of the Issuer's Board of Directors, (the \"Managing Directors\") are the managing directors of NLVM-III LLC and may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The Managing Directors, NLVA-III LP and NLVM-III LLC each disclaim Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of their respective pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Ordinary Shares","underlying_shares":148603},"source":{"system":"sec-edgar","filing":"0001209191-18-034404","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1340806/000120919118034404/doc4.xml","form_type":"4"}}],"next_cursor":"2018-05-31T16:54:17.000000Z,3912134"}